Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant
The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against...
Source: fnarena.com